目的对医院新引进的瓦里安Trilogy直线加速器按照国际原子能机构(IAEA)TRS277号报告进行光子束和电子束吸收剂量的测量和标定,将吸收剂量在参考条件下标定为1 MU=1 c Gy,确保输出剂量准确,以便后期的投入临床使用。方法采用德国PTW公司...目的对医院新引进的瓦里安Trilogy直线加速器按照国际原子能机构(IAEA)TRS277号报告进行光子束和电子束吸收剂量的测量和标定,将吸收剂量在参考条件下标定为1 MU=1 c Gy,确保输出剂量准确,以便后期的投入临床使用。方法采用德国PTW公司的UNDOS E型静电计和TW30013 0.6cc指形电离室和普通三维水箱现场测量Trilogy直线加速器光子束和电子束的吸收剂量,然后通过调节加速器上剂量监测系统的电位器,使得机器输出1 MU=1 c Gy。结果经过测量和标定后,测得光子束和电子束的吸收剂量结果误差<1%。结论经过对Trilogy直线加速器光子束和电子束吸收剂量的测量和标定后,其输出剂量符合国家要求。展开更多
Three series of novel steroidal thiazole derivatives were synthesized by microwave assisted one-potreaction from pregnenolone, testosterone and estrone, respectively. Their structures were characterized by IR, NMRand ...Three series of novel steroidal thiazole derivatives were synthesized by microwave assisted one-potreaction from pregnenolone, testosterone and estrone, respectively. Their structures were characterized by IR, NMRand HRMS, and the antiproliferative activities of all the synthesized compounds against human cervical carcinoma(HeLa), human liver carcinoma(HepG2), human lung carcinoma(A549), nasopharyngeal carcinoma(CNE2) andnormal kidney epithelial cells(HEK293T) were screened. Among the compounds, 1-estron-17'-ylidene-2-[4'-(p-bromophenyl)-2'-thiazol]hydrazone(12) displayed distinct antiproliferative activity against all the tested cancercell lines and was almost inactive to normal kidney epithelial cells.展开更多
文摘目的对医院新引进的瓦里安Trilogy直线加速器按照国际原子能机构(IAEA)TRS277号报告进行光子束和电子束吸收剂量的测量和标定,将吸收剂量在参考条件下标定为1 MU=1 c Gy,确保输出剂量准确,以便后期的投入临床使用。方法采用德国PTW公司的UNDOS E型静电计和TW30013 0.6cc指形电离室和普通三维水箱现场测量Trilogy直线加速器光子束和电子束的吸收剂量,然后通过调节加速器上剂量监测系统的电位器,使得机器输出1 MU=1 c Gy。结果经过测量和标定后,测得光子束和电子束的吸收剂量结果误差<1%。结论经过对Trilogy直线加速器光子束和电子束吸收剂量的测量和标定后,其输出剂量符合国家要求。
基金Project supported by the National Natural Science Foundation of China(Nos.21672084,21372090)the Special Fund Project of Department of Natural Resources of Guangdong Province(Guangdong Natural Resources Cooperation)(No.2020037)。
文摘Three series of novel steroidal thiazole derivatives were synthesized by microwave assisted one-potreaction from pregnenolone, testosterone and estrone, respectively. Their structures were characterized by IR, NMRand HRMS, and the antiproliferative activities of all the synthesized compounds against human cervical carcinoma(HeLa), human liver carcinoma(HepG2), human lung carcinoma(A549), nasopharyngeal carcinoma(CNE2) andnormal kidney epithelial cells(HEK293T) were screened. Among the compounds, 1-estron-17'-ylidene-2-[4'-(p-bromophenyl)-2'-thiazol]hydrazone(12) displayed distinct antiproliferative activity against all the tested cancercell lines and was almost inactive to normal kidney epithelial cells.